Artelo Biosciences FY23 EPS $(3.14) Vs $(3.56) YoY
Portfolio Pulse from Benzinga Newsdesk
Artelo Biosciences reported its FY23 financial results, showing an EPS of $(3.14) compared to $(3.56) YoY. The company's cash and investments stood at $10.4 million, with R&D expenses at $5.7 million and G&A expenses at $4.2 million. The net loss for the year was $9.3 million, an improvement from the previous year's $10.1 million.
March 25, 2024 | 12:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Artelo Biosciences reported an improved EPS of $(3.14) for FY23, a decrease in net loss to $9.3 million, and a solid cash position of $10.4 million.
The improvement in EPS and reduction in net loss indicate a positive financial trajectory for Artelo Biosciences. The solid cash position suggests the company has a buffer for its operations and investments, potentially making ARTL more attractive to investors in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100